文献速递肝病

原发性胆汁性胆管炎的血清蛋白质组与熊去氧胆酸应答

The Serum Proteome and Ursodeoxycholic Acid Response in Primary Biliary Cholangitis.
PubMed 文献 · Hepatology · 2021-11-02

用CXCL11和CCL20区分应答状态的线性判别分析AUC为0.91(CI 0.83-0.91),提示趋化因子升高与UDCA应答不佳相关。

要点

  • UDCA治疗未完全消除PBC患者的炎症蛋白质组特征。
  • CXCL11和CCL20区分UDCA应答状态的AUC为0.91。

核心结论

  • PBC中UDCA应答不佳以血清趋化因子升高为特征,可能与细胞衰老及BEC释放有关,并有望成为高风险疾病的生物标志物。

研究设计与样本

  • 英国PBC队列研究,对526例受试者和97名健康对照进行发现期血清蛋白质组学(Olink)及靶向多重验证。

主要发现

  • 未治疗PBC患者(n=68)呈现炎症蛋白质组,UDCA治疗(n=416)后规模通常减小但未消退。
  • 所有6种趋化因子在发现和验证队列中均显示UDCA应答者与无应答者间显著差异表达。
  • 使用CXCL11和CCL20血清水平判别应答状态的线性判别分析AUC为0.91(CI 0.83-0.91)。

临床怎么用

  • 血清趋化因子(如CXCL11和CCL20)有潜力作为识别PBC高风险疾病和UDCA应答不佳的生物标志物,其临床效用需在前瞻性研究中进一步评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Stratified therapy has entered clinical practice in primary biliary cholangitis (PBC), with routine use of second-line therapy in nonresponders to first-line therapy with ursodeoxycholic acid (UDCA). The mechanism for nonresponse to UDCA remains, however, unclear and we lack mechanistic serum markers. The UK-PBC study was established to explore the biological basis of UDCA nonresponse in PBC and identify markers to enhance treatment. APPROACH AND RESULTS: Discovery serum proteomics (Olink) with targeted multiplex validation were carried out in 526 subjects from the UK-PBC cohort and 97 healthy controls. In the discovery phase, untreated PBC patients (n = 68) exhibited an inflammatory proteome that is typically reduced in scale, but not resolved, with UDCA therapy (n = 416 treated patients). Nineteen proteins remained at a significant expression level (defined using stringent criteria) in UDCA-treated patients, six of them representing a tightly linked profile of chemokines (including CCL20, known to be released by biliary epithelial cells (BECs) undergoing senescence in PBC). All showed significant differential expression between UDCA responders and nonresponders in both the discovery and validation cohorts. A linear discriminant analysis, using serum levels of C-X-C motif chemokine ligand 11 and C-C motif chemokine ligand 20 as markers of responder status, indicated a high level of discrimination with an AUC of 0.91 (CI, 0.83-0.91). CONCLUSIONS: UDCA under-response in PBC is characterized by elevation of serum chemokines potentially related to cellular senescence and was previously shown to be released by BECs in PBC, suggesting a potential role in the pathogenesis of high-risk disease. These also have potential for development as biomarkers for identification of high-risk disease, and their clinical utility as biomarkers should be evaluated further in prospective studies.

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Barron-Millar B, Ogle L, Mells G, et al. The Serum Proteome and Ursodeoxycholic Acid Response in Primary Biliary Cholangitis. Hepatology. 2021. PMID: 34129689. doi:10.1002/hep.32011

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。